Oryzon Genomics, S.A.

Oryzon Genomics has a liquidity position characterized by a current ratio of 1.95, indicating the company can cover its short-term liabilities with its short-term assets. However, the company's free cash flow is negative at -13.45 million EUR, and operating cash flow is also negative at -2.36 million EUR, suggesting ongoing cash outflows from operations. The company's cash and equivalents amount to 3.00 million EUR, which is insufficient to cover its long-term debt of 7.63 million EUR, resulting in a net cash position that is negative after subtracting total debt.

The company's profitability metrics are negative, with a return on equity of -2.21% and a return on assets of -1.80%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The gross profit is negative at -1.73 million EUR, and the operating income is -5.71 million EUR, further highlighting the company's unprofitable operations.

Oryzon Genomics does not disclose specific revenue by segments or geographic regions, making it difficult to assess the concentration of its revenue sources. The lack of detailed segment reporting suggests that the company's operations are not diversified, and its financial performance is likely heavily influenced by a single product or market.

The company's growth trajectory is uncertain, as it has not provided specific revenue growth projections for the current or next fiscal year. The negative operating and free cash flows indicate that the company is not currently generating sufficient cash to support growth initiatives or expand its operations. The absence of positive cash flows from operations suggests that the company may need to rely on external financing to fund its activities.

The risk assessment for Oryzon Genomics indicates a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative free cash flow and insufficient cash reserves to cover its long-term debt. The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted shares, suggesting no imminent threat of share dilution. The company's financial position is further complicated by its negative net income and operating income, which may impact its ability to meet its financial obligations.

Recent events and filings for Oryzon Genomics include analyst estimates that suggest a mixed outlook. The mean price target is 7.30 EUR, with a median of 6.00 EUR, and a high of 12.00 EUR. The mean recommendation from analysts is 1.67, indicating a generally positive outlook, with 2 strong-buy and 4 buy ratings. These analyst estimates suggest that while there is optimism about the company's potential, the current financial performance and cash flow challenges may limit the upside for investors.